(Reuters) - The settlement collapsed when state attorneys general opposed the deal as anti-competitive. Apotex then flooded the United States with its cheaper form of Plavix, causing sales of Bristol's branded product to plunge.
Bristol-Myers said on Tuesday that it was also cooperating fully with a previously disclosed criminal probe of the proposed Apotex settlement being conducted by the antitrust division of the U.S. Department of Justice.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment